Cargando…
Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis
Takayasu arteritis (TAK) is a less common large vessel vasculitis where histopathology of involved arteries is difficult to access except during open surgical procedures. Assessment of disease activity in TAK, therefore, relies on surrogate measures. Clinical disease activity measures such as the Na...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601573/ https://www.ncbi.nlm.nih.gov/pubmed/36292253 http://dx.doi.org/10.3390/diagnostics12102565 |
_version_ | 1784817098697998336 |
---|---|
author | Misra, Durga Prasanna Jain, Neeraj Ora, Manish Singh, Kritika Agarwal, Vikas Sharma, Aman |
author_facet | Misra, Durga Prasanna Jain, Neeraj Ora, Manish Singh, Kritika Agarwal, Vikas Sharma, Aman |
author_sort | Misra, Durga Prasanna |
collection | PubMed |
description | Takayasu arteritis (TAK) is a less common large vessel vasculitis where histopathology of involved arteries is difficult to access except during open surgical procedures. Assessment of disease activity in TAK, therefore, relies on surrogate measures. Clinical disease activity measures such as the National Institutes of Health (NIH) score, the Disease Extent Index in TAK (DEI.TAK) and the Indian TAK Clinical Activity Score (ITAS2010) inconsistently associate with acute phase reactants (APRs). Computerized tomographic angiography (CTA), magnetic resonance angiography (MRA), or color Doppler Ultrasound (CDUS) enables anatomical characterization of stenosis, dilatation, and vessel wall characteristics. Vascular wall uptake of 18-fluorodeoxyglucose or other ligands using positron emission tomography computerized tomography (PET-CT) helps assess metabolic activity, which reflects disease activity well in a subset of TAK with normal APRs. Angiographic scoring systems to quantitate the extent of vascular involvement in TAK have been developed recently. Erythrocyte sedimentation rate and C-reactive protein have a moderate performance in distinguishing active TAK. Numerous novel biomarkers are under evaluation in TAK. Limited literature suggests a better assessment of active disease by combining APRs, PET-CT, and circulating biomarkers. Validated damage indices and patient-reported outcome measures specific to TAK are lacking. Few biomarkers have been evaluated to reflect vascular damage in TAK and constitute important research agenda. |
format | Online Article Text |
id | pubmed-9601573 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96015732022-10-27 Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis Misra, Durga Prasanna Jain, Neeraj Ora, Manish Singh, Kritika Agarwal, Vikas Sharma, Aman Diagnostics (Basel) Review Takayasu arteritis (TAK) is a less common large vessel vasculitis where histopathology of involved arteries is difficult to access except during open surgical procedures. Assessment of disease activity in TAK, therefore, relies on surrogate measures. Clinical disease activity measures such as the National Institutes of Health (NIH) score, the Disease Extent Index in TAK (DEI.TAK) and the Indian TAK Clinical Activity Score (ITAS2010) inconsistently associate with acute phase reactants (APRs). Computerized tomographic angiography (CTA), magnetic resonance angiography (MRA), or color Doppler Ultrasound (CDUS) enables anatomical characterization of stenosis, dilatation, and vessel wall characteristics. Vascular wall uptake of 18-fluorodeoxyglucose or other ligands using positron emission tomography computerized tomography (PET-CT) helps assess metabolic activity, which reflects disease activity well in a subset of TAK with normal APRs. Angiographic scoring systems to quantitate the extent of vascular involvement in TAK have been developed recently. Erythrocyte sedimentation rate and C-reactive protein have a moderate performance in distinguishing active TAK. Numerous novel biomarkers are under evaluation in TAK. Limited literature suggests a better assessment of active disease by combining APRs, PET-CT, and circulating biomarkers. Validated damage indices and patient-reported outcome measures specific to TAK are lacking. Few biomarkers have been evaluated to reflect vascular damage in TAK and constitute important research agenda. MDPI 2022-10-21 /pmc/articles/PMC9601573/ /pubmed/36292253 http://dx.doi.org/10.3390/diagnostics12102565 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Misra, Durga Prasanna Jain, Neeraj Ora, Manish Singh, Kritika Agarwal, Vikas Sharma, Aman Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis |
title | Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis |
title_full | Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis |
title_fullStr | Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis |
title_full_unstemmed | Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis |
title_short | Outcome Measures and Biomarkers for Disease Assessment in Takayasu Arteritis |
title_sort | outcome measures and biomarkers for disease assessment in takayasu arteritis |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9601573/ https://www.ncbi.nlm.nih.gov/pubmed/36292253 http://dx.doi.org/10.3390/diagnostics12102565 |
work_keys_str_mv | AT misradurgaprasanna outcomemeasuresandbiomarkersfordiseaseassessmentintakayasuarteritis AT jainneeraj outcomemeasuresandbiomarkersfordiseaseassessmentintakayasuarteritis AT oramanish outcomemeasuresandbiomarkersfordiseaseassessmentintakayasuarteritis AT singhkritika outcomemeasuresandbiomarkersfordiseaseassessmentintakayasuarteritis AT agarwalvikas outcomemeasuresandbiomarkersfordiseaseassessmentintakayasuarteritis AT sharmaaman outcomemeasuresandbiomarkersfordiseaseassessmentintakayasuarteritis |